Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma
Authors:
- H SchmidtHSH Schmidt
- B S SørensenBSB S Sørensen
- H von der MaaseHMH von der Maase
- C BangCBC Bang
- R AggerRAR Agger
- M HoklandMHM Hokland
- E NexoE Nexo
- 1 December 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 12 (6) , 585-592
Abstract
Circulating malignant cells in peripheral blood are thought to be precursors and surrogate markers of distant metastases and hence markers of a poor clinical outcome. In this study, we used the detection of MART-1 and tyrosinase (TYR) mRNA with a quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay to identify circulating melanoma cells. Blood samples were obtained from 35 patients with metastatic melanoma before, during and after treatment with interleukin-2, interferon-α and cisplatin. In addition, MART-1 and TYR protein was identified by immunohistochemistry in consecutive biopsies from 15 of the patients. Analysis of three daily blood samples for 3 days demonstrated that four out of 11 patients examined were negative for both markers on all occasions, and two patients were positive for both markers on all occasions but one. The remaining five patients showed sporadic low positive results for one or the other of the two markers. By comparing the immunohistochemistry results from consecutive biopsies with the RT-PCR results, we demonstrated that patients with MART-1 and TYR protein in their tumour cells had circulating MART-1 and TYR mRNA in 77% and 54% of the cases, respectively. During treatment, the majority of patients who were positive for MART-1 and TYR mRNA converted to being negative. However, these conversions did not significantly correlate with objective response. The presence of TYR mRNA in one of the first two samples showed a trend towards being an independent prognostic factor for poor survival.Keywords
This publication has 22 references indexed in Scilit:
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999
- Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.Journal of Clinical Oncology, 1998
- Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2Annals of Surgery, 1998
- Lymph node micrometastases of cutaneous melanoma: Increased sensitivity of molecular diagnosis in comparison to immunohistochemistryInternational Journal of Cancer, 1998
- Prognostic factors for survival of patients treated systemically for disseminated melanoma.Journal of Clinical Oncology, 1998
- The Analysis of Tyrosinase-Specific mRNA in Blood Samples of Melanoma Patients by RT-PCR Is Not a Useful Test for Metastic Tumor ProgressionJournal of Investigative Dermatology, 1997
- Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.Proceedings of the National Academy of Sciences, 1994
- Detection of Residual Tumor Cells in Patients with Malignant Melanoma Responding to ImmunotherapyJournal of Immunotherapy, 1994
- Pigmentation Genes: the Tyrosinase Gene Family and the pmel 17 Gene FamilyJournal of Investigative Dermatology, 1993
- Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reactionThe Lancet, 1991